Top Markets
Coin of the day
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Classement en actions #25524
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Prix de l'action
$9.81
Dernière synchronisation: 2025-03-18
Capitalisation boursière
$48.68M
Changement (1 jour)
1.55%
Changement (1 an)
0.00%
Pays
US
Échange AlloVir, Inc. (ALVR)

Catégorie

Bénéfices pour AlloVir, Inc. (ALVR)
Bénéfices en Jun 2026 TTM : $-54.46M
Selon les derniers rapports financiers de AlloVir, Inc., les bénéfices actuels de l'entreprise sont de $-54.46M. En 2023, l'entreprise a réalisé un bénéfice de $-190.54M, une diminution par rapport à celui de 2022 qui était de $-168.98M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour AlloVir, Inc. de 2018 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-54.46M -7.33%
2024 $-58.77M -69.16%
2023 $-190.54M 12.76%
2022 $-168.98M -1.16%
2021 $-170.96M 144.98%
2020 $-69.78M 192.73%
2019 $-23.84M 881.03%
2018 $-2.43M 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
$5.27B -9,786.00%
US
$1.95B -3,681.87%
NL
$1.61B -3,064.22%
AU
- -
CH
$-3.09B 5,568.48%
US